Thu, December 19, 2024
[ Thu, Dec 19th 2024 ] - WSPA
Limitless Fit-3 Mobility Exercises
Wed, December 18, 2024
[ Wed, Dec 18th 2024 ] - fbcnews
Lovo on a quest to fulfil his dream
Tue, December 17, 2024
[ Tue, Dec 17th 2024 ] - AOL
Get paid to work out with these 9 apps
[ Tue, Dec 17th 2024 ] - MSN
Gym wins fitness title
Mon, December 16, 2024
[ Mon, Dec 16th 2024 ] - Science Daily
Teen Health News
[ Mon, Dec 16th 2024 ] - Uber
Health & Fitness App 2024 Market Map
Sun, December 15, 2024
[ Sun, Dec 15th 2024 ] - Los Angeles Times
The Power of Resiliency
[ Sun, Dec 15th 2024 ] - kathmandupost
Nepal's trail opportunities

Is Bristol-Myers Squibb Company (BMY) the Best Weight Loss Stock to Buy Now According to Hedge Funds?


//health-fitness.news-articles.net/content/2024/ .. s-stock-to-buy-now-according-to-hedge-funds.html
Published in Health and Fitness on Tuesday, December 17th 2024 at 7:43 GMT by MSN   Print publication without navigation

  • We recently compiled a list of the 12 Best Weight Loss Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the other weight loss stocks.

The article from MSN discusses whether Bristol Myers Squibb (BMS) is a good investment for those interested in the weight loss sector. It highlights that while BMS is not primarily known for weight loss drugs, its acquisition of Karuna Therapeutics, which focuses on treatments for psychiatric and neurological conditions, could indirectly influence its attractiveness to investors in the health sector. The article notes that hedge funds have shown significant interest in BMS, with 70 hedge funds holding positions in the company as of the end of the third quarter, indicating strong institutional backing. However, the piece also points out that BMS's current pipeline does not directly target weight loss, but rather focuses on oncology, immunology, and cardiovascular diseases. The discussion revolves around the broader implications of BMS's strategic moves and its potential in adjacent health markets, suggesting that while not the most direct play for weight loss stocks, BMS could still be a compelling investment due to its diversified portfolio and the potential for its treatments to intersect with metabolic health issues.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/health/weightloss/is-bristol-myers-squibb-company-bmy-the-best-weight-loss-stock-to-buy-now-according-to-hedge-funds/ar-AA1w1c0F ]

Publication Contributing Sources